Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Breast Cancer Research : Bcr
Kurozumi, Sasagu S; Alsaleem, Mansour M; Monteiro, CĂntia J CJ; Bhardwaj, Kartikeya K; Joosten, Stacey E P SEP; Fujii, Takaaki T; Shirabe, Ken K; Green, Andrew R AR; Ellis, Ian O IO; Rakha, Emad A EA; Mongan, Nigel P NP; Heery, David M DM; Zwart, Wilbert W; Oesterreich, Steffi S; Johnston, Simon J SJ
Martelotto, Luciano G LG; Ng, Charlotte Ky CK; De Filippo, Maria R MR; Zhang, Yan Y; Piscuoglio, Salvatore S; Lim, Raymond S RS; Shen, Ronglai R; Norton, Larry L; Reis-Filho, Jorge S JS; Weigelt, Britta B
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Cancer Discovery
Bose, Ron R; Kavuri, Shyam M SM; Searleman, Adam C AC; Shen, Wei W; Shen, Dong D; Koboldt, Daniel C DC; Monsey, John J; Goel, Nicholas N; Aronson, Adam B AB; Li, Shunqiang S; Ma, Cynthia X CX; Ding, Li L; Mardis, Elaine R ER; Ellis, Matthew J MJ